Almirall

Almirall edificio id

Almirall announces new sustainability strategy with 20 lines of action such as Zero Net Emissions Plan

Alphavalue / Divacons | The pharmaceutical company launched the new sustainability strategy ‘Act4Impact 2030’ to transform its approach to sustainability, focusing on five main pillars: ‘Planet’, ‘People’, ‘Patients’, ‘Partners’ and ‘Principles’. The ‘Act4Impact’ strategy consists of 20 strategic lines of action that will be monitored over time to assess progress. These include the deployment of its roadmap towards Zero Net Emissions through energy decarbonisation plans, sustainable mobility or supplier engagement…


Almirall edificio id

Almirall: investors to focus on Lebrikizumab Pipeline, sales of which could peak at €450m

Morgan Stanley: Analyst Thibault Boutherin expects the stock to be flat or slightly down post-results following the lowering of guidance for FY24, but reiterates that all medium-term drivers remain intact. Almirall posted EBITDA 3-4% below consensus and guidance for H1 2024 sales 2% below consensus and EBITDA 4% below consensus. However, Thibault expects investors to focus on the Lebrikizumab Pipeline, where sales could peak at €450 million.


Almirall edificio id

EMA gives thumbs up to Almirall’s atopic dermatitis medicine Lebrikizumab

Bankinter: Ebglyss (lebrikizumab) receives positive opinion from the European Medical Agency’s advisory committee. The Target Price is raised from €9.50/share to €10/share . The positive opinion of the committee has to be reviewed by the European Commission, which issues the marketing authorisation. This step could take 2-3 months and, if ratified, the commercial launch of Ebglyss will be almost immediate. The drug is a treatment for moderate to severe atopic…


Almirall edificio id

Almirall’s rebound from June lows of almost 40% leaves fastest indicators overbought

Renta 4| The price has violently broken the downward trend line from the highs of July 2021, while confirming important bullish divergences in its slow indicators. Moreover, the monthly indicators have started a bullish process, which is often accompanied by additional upward pressure in the medium/long term. The price presents a key reversal support level, between the lows of last June at €7.15 and the crossing of the main bullish…


Almirall edificio id

Almirall acquires rights to distribute Alzheimer’s treatment in Spain for an initial €45 million

Bankinter| Laboratorios Almirall (ALM) has acquired the rights to distribute a product to treat Alzheimer’s disease in Spain. The agreement gives Almirall exclusive rights to a transdermal patch containing Rivastigmine to treat Alzheimer’s disease. The transaction has been closed for an upfront payment of €45 million and provides for additional potential compliance payments of up to €15 million. Assessment: Positive news, the company has been looking for acquisitions to strengthen…


Almirall

Positive Results From Phase III Study For Lebrikizumab; Almirall Will Seek Commercial Authorisation

Bankinter | Lebrikizumab is a new treatment being developed for atopical dermatitis licensed by Eli Lilly to Almirall (ALM). In the third study in Phase III, it has shown to have had a significant improvement on the skin, relieving itching for people with this ailment when combined with topical corticosteroids. The study has met all the primary valuation criteria and the principal secondary ones, and has a security profile consistent…


Almirall

Almirall: recent revaluation (+46%) reduces potential 13.1%

I. Isardo (Link Securities) | Almirall (ALM) is a vertically integrated international pharmaceutical group which focuses on the purchase, production, storage, commercialisation and mediation in the sale of specialities and pharmaceutical products and of all types of raw materials used in the production of specialities and pharmaceutical products.


Almirall

Almirall: recommendation raised from Sell to Neutral

Bankinter | Almirall Q1’18 results were better than expected, with sales of 189.3 million euros (-0.1%); Ebitda of 58 million (+5.4%); Net Attributable Profit of 30.9 million (+57.1%) and net debt of 150 million euros. Finally, the DN/PN ratio has reached 7.4%.



No Picture

Almirall, Campofrío and Sacyr, the most recommended values in the Spanish market

MADRID | By Jaime Santisteban | Almirall, Campofrío and Sacyr are the most recommended values in the Spanish market, according the market consensus. Repsol turned down the offer to renew its two seats in the YPF ‘s board on Tuesday, and fixed its eyes in Norway instead. Also, unemployment in Spain reportedly dropped by 111,565 people in April. “Although this means a turning point in the Spanish economic recovery, the country remains in the deep well,” The Corner senior analyst Fernando G. Urbaneja explains.